Saturday 17 October 2026
Export RCEL’s income statement to Excel — free account
Avita Medical Inc.
RCEL Healthcare Medical Devices
Avita Medical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $71.6 million, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 17.8%, EPS grew 33.8%, free cash flow grew 66.5% and total debt rose 10.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
13.04
0.37
−2.76%
Follow RCEL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.10 | 0.07 | 0.08 | 0.08 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.39) | (0.88) | (0.56) | (1.82) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.94 | 0.99 | 1.09 | 1.10 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.01) | (2.28) | (2.55) | (3.44) | |
EV/FCF |
(1.82) | (2.15) | (2.42) | (3.28) | |
Quick Ratio |
0.52 | 0.44 | 0.36 | 0.31 | |
Current Ratio |
0.67 | 0.57 | 0.47 | 0.41 | |
Net Debt/EBITDA |
(1.69) | (2.56) | (3.72) | (6.39) | |
Debt/Assets |
66.61% | 76.22% | 89.51% | 97.66% | |
Debt/Equity |
(6.37) | (2.58) | (1.99) | (1.68) | |
Asset Turnover |
1.00 | 1.05 | 1.19 | 1.43 | |
Operating CF/Net income |
0.40 | 0.47 | 0.95 | 0.46 | |
Capex/Depreciation |
(1.63) | 0.06 | (0.03) | (0.18) | |
Interest Coverage |
(9.39) | (8.30) | (6.46) | (4.22) | |
Research and Development Expense of Revenue |
21.97% | 32.30% | 29.24% | 23.40% | |
Selling, General and Administrative Expense of Revenue |
113.00% | 108.01% | 98.19% | 90.06% | |
Intangible Assets out of Total Assets |
0.08 | 0.10 | 0.11 | 0.11 | |
Share Based Compensation of Revenue |
16.28% | 7.79% | 5.72% | 9.16% | |
Graham Net Nets |
(4.00) | (7.81) | (7.62) | (7.44) | |
Graham Number |
61.83 | 96.85 | 103.32 | 108.19 | |
Earnings Yield |
(708.08%) | (1,011.00%) | (845.22%) | (695.71%) | |
Free Cash Flow Yield |
(514.37%) | (687.12%) | (576.70%) | (400.54%) | |
Revenue per Share |
12.02 | 12.65 | 12.61 | 14.12 | |
Operating CF per Share |
(3.68) | (3.90) | (6.60) | (2.27) | |
Capex per Share |
(0.66) | 0.03 | (0.01) | (0.07) | |
Free Cash Flow per Share |
(4.33) | (3.88) | (6.61) | (2.34) | |
Cash per Share |
16.42 | 13.05 | 9.34 | 7.24 | |
Shareholders Equity per Share |
(4.70) | (11.95) | (15.17) | (18.11) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(4.70) | (11.95) | (15.17) | (18.11) | |
Free Cash Flow |
(6.15) | (5.40) | (10.09) | (3.60) | |
Working Capital |
(20.46) | (27.19) | (35.02) | (40.32) | |
Capital Expenditures |
(0.93) | 0.04 | (0.02) | (0.11) | |
Net Current Asset Value |
(29.03) | (37.55) | (43.06) | (47.22) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.00 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
9.71 | 10.44 | 10.97 | 10.61 | |
Average Payables |
6.15 | 7.63 | 7.95 | 6.85 | |
Average Inventory |
6.73 | 7.10 | 7.26 | 6.41 | |
Average Assets |
72.39 | 68.05 | 60.55 | 52.96 | |
Average Common Equity |
2.78 | (6.08) | (13.87) | (20.36) |
Columns are period end dates